The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: An analysis of the Singapore multiple myeloma study group

European Journal of Haematology

Volumn 89, Issue 2, 2012, Pages 136-144

  Tan, Daryl ^a   Ong, Kiat H ^b   Koh, Liang P ^c   Wong, Siew S ^b   Khin, Myat T ^c   Lee, Lai H ^a   Goh, Yeow T ^a   Chng, Wee J ^c,d  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bortezomib; Cytogenetics; Myeloma; Risk stratification

Indexed keywords

BORTEZOMIB; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK MANAGEMENT; SINGAPORE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE MORAL JUDGMENT; RISK FACTORS; SINGAPORE; SURVIVAL RATE; TIME FACTORS;

EID: 84863840340     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01797.x     Document Type: Article

References (41)

1. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-7.
2. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisolone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006;108:2168-72.
3. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85.
4. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-200.
5. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85.
6. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9.
7. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009;84:1095-110.
8. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
9. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66.
10. Arzoumanian V, Hoering A, Sawyer J, et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008;22:850-5.
11. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, Greipp PR, Gertz MA. Cytogenetic abnormalities correlate with the plasma cell labelling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113:73-7.
12. Boccadoro M, Massaia M, Dianzani U, et al. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. Haematologica 1987;72:171-5.
13. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999;13:1295-314.
14. Tan D, Teoh G, Lau LC, et al. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. Am J Hematol 2010;85:752-6.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc 1958;53:457-84.
16. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973;29:579-84.
17. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
18. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
19. Durie BG, Harousseau JL, San Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
20. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
21. Fonseca R. Many and multiple myeloma(s). Leukemia 2003;17:1943-4.
22. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
23. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529-34.
24. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6.
25. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9.
26. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-7.
27. Morgan JG, Davies EF, Gregory MW, et al. Thalidomide maintenance significantly improves progression-free survival (PFS) and overall survival (OS) of myeloma patients when effective relapse treatments are used: MRC Myeloma IX results. Blood 2010;116:623.
28. Zamagni E, Testoni N, Terragna C, et al. Prognostic impact of cytogenetic abnormalities on outcomes of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: an analysis of 593 patients. Blood 2010;116:21s.
29. Kapoor P, Kumar S, Mandrekar SJ, et al. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia 2011;25:1195-7.
30. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-84.
31. Avet-Loiseau H, Durie B, Haessler J, et al. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9, 897 patients. Blood 2009;114:21s. (suppl; abstr 743).
32. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4.
33. Rosiñol L, Cibeira MT, Mateos MV, et al. A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) In multiple myeloma: superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood 2009;116:21. (suppl; abstr 307).
34. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) Vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 2009;116:21. (suppl; abstr 40).
35. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009;27:5720-6.
36. Lahuerta J, Mateos M, Marti{dotless}'nez-Lo0pez J, et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-82.
37. Hoering A, Crowley J, Shaughnessy JD Jr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009;114:1299-305.
38. Van de Velde H, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399-406.
39. Wang M, Delasalle K, Feng L, et al. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2010;45:498-504.
40. Dingli D, Pacheco JM, Nowakowski GS, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007;25:4933-7.
41. Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011;118:529-34.